Aligos Therapeutics (ALGS) Non-Current Assets (2019 - 2026)
Aligos Therapeutics' (ALGS) quarterly Non-Current Assets came in at $4.9 million in Q1 2026, down 34.23% YoY from $7.5 million in Q1 2025, and down 13.08% on a QoQ basis from $5.7 million in Q4 2025.
Aligos Therapeutics (ALGS) Non-Current Assets (2019 - 2026) Analysis & Trends
Aligos Therapeutics (ALGS) has 8 years of Non-Current Assets data on file, last reported at $4.9 million in Q1 2026.
- Quarterly Non-Current Assets fell 34.23% year-over-year to $4.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $23.7 million (down 28.84% YoY) and the FY2025 annual result came in at $5.7 million, down 28.69% from the prior year.
- Non-Current Assets slipped to $4.9 million in Q1 2026, from $5.7 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $15.4 million in Q1 2022 to a low of $4.9 million in Q1 2026.
- A 5-year average of $10.0 million and a median of $9.8 million in 2024 frame the typical range for Non-Current Assets.
- The widest YoY moves for Non-Current Assets: up 4.62% in 2022, down 57.51% in 2022.
- Tracing ALGS's Non-Current Assets over 5 years: stood at $13.1 million in 2022, then fell by 20.57% to $10.4 million in 2023, then retreated by 23.84% to $8.0 million in 2024, then declined by 28.69% to $5.7 million in 2025, then decreased by 13.08% to $4.9 million in 2026.
- The last three Non-Current Assets figures came in at $4.9 million (Q1 2026), $5.7 million (Q4 2025), and $6.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.24 Bn | 131.39 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 86.01 Bn | 78.02 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 65.61 Bn | 60.42 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 56.92 Bn | 51.78 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 42.17 Bn | 37.07 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.27 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 27.77 Bn | 9.38 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.52 Bn | 26.36 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.36 Bn | 26.52 Bn | - | 18.06 Bn |
| 10 | Aligos Therapeutics | 70.20 Mn | 39.76 Mn | - | 4.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.20 Mn |
| Mar 31, 2026 | 4.93 Mn |
| Dec 31, 2025 | 5.67 Mn |
| Sep 30, 2025 | 6.33 Mn |
| Jun 30, 2025 | 6.76 Mn |
| Mar 31, 2025 | 7.49 Mn |
| Dec 31, 2024 | 7.95 Mn |
| Sep 30, 2024 | 8.60 Mn |
| Jun 30, 2024 | 9.24 Mn |
| Mar 31, 2024 | 9.84 Mn |
| Dec 31, 2023 | 10.44 Mn |
| Sep 30, 2023 | 11.21 Mn |
| Jun 30, 2023 | 11.89 Mn |
| Mar 31, 2023 | 12.31 Mn |
| Dec 31, 2022 | 13.15 Mn |
| Sep 30, 2022 | 13.98 Mn |
| Jun 30, 2022 | 14.84 Mn |
| Mar 31, 2022 | 15.39 Mn |
| Dec 31, 2021 | 30.95 Mn |
| Sep 30, 2021 | 14.40 Mn |